Phaseline

Companies › Lycia Therapeutics

Lycia Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LCA-0061
Antibody-based therapeutic designed to selectively bind and rapidly clear immunoglobulin E
IGHMPhase 1Atopic DiseaseApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07701954LCA-0061Phase 1Atopic DiseaseImmunologyApr 2028

Targets

IGHM (1)

Companies with the same targets

RAPT Therapeutics, Inc., a member of the GSK plc group of companies

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.